Source: PHARMAC
Information on what the Pharmacology and Therapeutics Advisory Committee (PTAC) will be considering at its upcoming meeting in November 2026.
Applications
Dienogest (Visanne or generic) for endometriosis
The Committee will discuss an application for dienogest as a first-line hormonal treatment for people with endometriosis. Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, which can cause pain and other symptoms.
Application for dienogest (Visanne or generic) for endometriosis(external link)
Relugolix with oestradiol and norethisterone acetate (Ryeqo) for endometriosis
The Committee will discuss an application for relugolix with oestradiol and norethisterone acetate (Ryeqo) as a second-line hormonal treatment for people with endometriosis who have previously received medical and/or surgical treatment and require ongoing management.
Faricimab for neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) previously been treated with aflibercept.
Aflibercept (Eylea) for wet age-related macular degeneration, 3rd-line.
Switching between aflibercept and faricimab when clinically indicated.
Neovascular (wet) age-related macular degeneration (wAMD) and diabetic macular oedema (DMO) affect the retina and can cause worsening vision and, if left untreated, may lead to vision loss. These three applications will be considered as part of a broader review of third-line vascular endothelial growth factor (anti-VEGF) treatments for wAMD and DMO.
Zolmitriptan for migraine attacks
The Committee will discuss an application for zolmitriptan for the treatment of migraine attacks. Migraine is a neurological condition that can cause severe headaches and symptoms such as nausea and sensitivity to light and sound.
Application for Zolmitriptan for acute migraine(external link)
Diabetic Oral Feed (Glucerna Liquid 220mL and Powder 800g) for nutritional support
The Committee will discuss an application for Diabetic Oral Feed 1 kcal/mL (Glucerna Liquid Vanilla 220 mL) for people with type 1 or type 2 diabetes and/or impaired glucose tolerance who are experiencing malnutrition and/or unintentional weight loss and require nutritional support. The supplier has also proposed a powder formulation (Glucerna Powder 800g) for the same indication. Oral nutritional supplements can help people meet their nutritional requirements when these cannot be met through their usual diet alone.
Tacrolimus ointment for atopic dermatitis
The Committee will discuss an application for tacrolimus ointment for the treatment of atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin condition that can cause itching, skin inflammation and impact quality of life
Application for Tacrolimus for atopic dermatitis(external link)
Empagliflozin and dulaglutide dual use for type 2 diabetes
The Committee will discuss an application for empagliflozin and dulaglutide to be used together for treatment of type 2 diabetes. These medicines are currently both funded, subject to criteria, but are not currently funded for use together. Type 2 diabetes is a long-term condition that affects the body’s ability to regulate blood glucose levels. Multiple treatments may be required to achieve optimal management of the condition.
Application for Empagliflozin and dulaglutide for type 2 diabetes(external link)
Budesonide, glycopyrronium bromide and formoterol fumarate triple therapy for severe asthma (Brezti)
The Committee will discuss an application for budesonide, glycopyrronium bromide and formoterol fumarate triple therapy (Brezti) for people living with difficult-to-control or severe asthma. Severe asthma can significantly impact daily life and may require treatment with multiple medicines to manage symptoms and reduce exacerbations.
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.
Original source: https://nz.mil-osi.com/2026/10/27/agenda-for-november-2026-pharmacology-and-therapeutics-advisory-committee-ptac-meeting/